Qiagen and Eppendorf form alliance

Friday, 03 February, 2006

Qiagen and Eppendorf have announced that they have formed a strategic alliance that includes co-development and co-marketing of complementary and optimised products. The alliance is intended to link the brands and product lines and to ensure the highest compatibility of their products targeting the research, applied testing and molecular diagnostics.

In addition, Qiagen has acquired Eppendorf's reagent business which includes the Eppendorf's Prime nucleic acid sample preparation and PCR reagent product lines and related intellectual property. The acquired assets represent an attractive portfolio of preanalytical and nucleic acid amplification consumables as well as a very promising pipeline of proprietary technologies for nucleic acid handling, separation, purification and amplification.

Through the alliance, Qiagen and Eppendorf intend to focus on improving biological sample management and analysis. The availability of combined and optimised products should create significant benefits for customers in research, applied testing and molecular diagnostics.

Related News

L'Oréal-UNESCO For Women In Science Fellows announced for ANZ

This year's program honours four women who are reshaping what leadership in research looks...

Peter Beattie appointed Chair of Brandon BioCatalyst

Brandon BioCatalyst has announced new board appointments to continue the scaling of Australian...

Virologist receives GSK Award for AI-based disease detection

Professor Edward Holmes has received the 2025 GSK Award for Research Excellence for his use of...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd